CH Biomedical Named to MIT Technology Review's "50 Smartest Companies" List

2022.07.29 24

On July 29, 2022, MIT Technology Review, a leading international science and technology media outlet, announced the results of its 2021 “50 Smartest Companies” (TR 50) list. CH Biomedical, recognized as a pioneering innovator in the global Ventricular Assist Device (VAD) field, earned a place on MIT Technology Review’s 2021 “50 Smartest Companies” list for its CH-VAD, a next-generation, fully magnetically levitated implantable left ventricular assist system (LVAD) — the first of its kind in China to be independently developed and approved by the National Medical Products Administration (NMPA).

Since 2010, MIT Technology Review has identified its “50 Smartest Companies (TR50)” each year from thousands of technology enterprises worldwide to spotlight key trends in emerging technologies. This recognition underscores the international scientific community’s strong endorsement of CH Biomedical’s R&D and innovation strength, marking its ascent into the ranks of global technology leaders.

CH Biomedical, Inc.(CHB) was founded in 2008 by a team of scientific and technological experts with overseas experience with the goal of bringing improved survival and quality of life to end-stage heart failure patients. 

Previous:CH Biomedical Successfully Achieves ISO 13485:2016 Quality Management System Certification Next:People's Daily Praises CH Biomedical for Surpassing International Technological Barriers and Benefiting Numerous Patients back
Hot

  • People's Daily Praises CH Biomedical for Surpassing International Technological Barriers and Benefiting Numerous Patients2023.08.07

    On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.

  • "CH-VAD Approval" Selected for Inclusion in China's Important Medical Advancements in 20212022.04.17

    Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.

  • Dr. Chen and Dr. Lin Invited to Deliver a Plenary Speech at The 2019 Gordon Research Conference 2019.09.30

    From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.

ABOUT US
Our Company
Milestones
PRODUCTS
Overview
CH-VAD®
NEWS
CAREERS
Talent Concept
Job Opportunities
CONTACT US
Contact
Copyright © 2021, BrioHealth Technologies, Inc. All rights reserved.